Thus, the potent inflammasome‐activating compound like (‐)‐maackiain could be useful clinically as an immune‐stimulating agent and supplemental influenza vaccine adjuvant to further increase caspase‐1‐augmented IL‐1β production. This evidence concerns the gene IL1B and influenza.